PUBLIC COMPANY
save$DAWNDay One Biopharmaceuticals, Inc.
$DAWN21.530.00%Brisbane, CA, USupdated 21d ago
community read0 votes
pipeline
4
marketed
1
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
3Phase 11Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
- phase1To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
- phase2Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
- phase1Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
- phase2A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- —Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER20,204 sh
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER300,000 sh
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER147,702 sh
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER18,197 sh
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER300,000 sh
- Apr 23, 26dispo to issuerBender Jeremy · CHIEF EXECUTIVE OFFICER808,285 sh
🐶 Hiring Signal
News
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 6d ago
- Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journeyExpedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.fiercebiotech · 16d ago
- Biopharma dealmaking in 2026: The recovery gathers speed in Q2It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expectat…endpoints · 29d ago
- Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73"There are some physicians that work to 100”: Dawn Zuidgeest-Craft on becoming a medical doctor in her 70s.stat · 2mo ago
- Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72“I know what I’m getting into”: Dawn Zuidgeest-Craft on starting medical residency at almost 73.stat · 2mo ago
- Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learnedStarting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.stat · 3mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that